首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL1F10 |
| Uniprot No | Q8WWZ1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MCSLPMARYYIIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLGIQGGSRCLACVETEEGPSLQLEDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSW |
| 预测分子量 | 32.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL1F10(IL-38)重组蛋白的3篇参考文献示例：
---
1. **文献名称**：*"IL-38: A novel cytokine in the IL-1 family involved in inflammatory regulation"*
**作者**：Smith A, et al.
**摘要**：研究报道了重组IL1F10(IL-38)蛋白的体外表达及功能，发现其通过抑制IL-1β和IL-6信号通路减轻巨噬细胞炎症反应，提示其潜在抗炎作用。
2. **文献名称**：*"Recombinant IL-38 modulates Th17 responses in autoimmune arthritis"*
**作者**：Chen L, et al.
**摘要**：通过大肠杆菌系统表达重组IL-38蛋白，实验证明其可降低胶原诱导关节炎模型小鼠的Th17细胞分化，为治疗自身免疫疾病提供新策略。
3. **文献名称**：*"Structural and functional characterization of recombinant human IL-38"*
**作者**：Wang Y, et al.
**摘要**：解析了重组人源IL-38蛋白的晶体结构，发现其与IL-1受体拮抗剂(IL-1Ra)具有相似结合域，可能通过竞争性抑制IL-1家族受体发挥调控作用。
---
注：以上文献信息为示例性概括，实际引用需根据具体研究内容查询真实发表的论文(可通过PubMed或Web of Science检索关键词“IL-38 recombinant”或“IL1F10 protein”获取)。
**Background of IL1F10 Recombinant Protein**
IL1F10. also known as interleukin-36 receptor antagonist (IL-36Ra) or IL-36RN, is a member of the interleukin-1 (IL-1) cytokine family. This family comprises key regulators of innate immunity and inflammation, with IL1F10 specifically functioning as a natural antagonist to pro-inflammatory IL-36 signaling. IL-36 cytokines (IL-36α, IL-36β, IL-36γ) bind to the IL-36 receptor (IL-36R), activating NF-κB and MAPK pathways to drive inflammatory responses in skin, lung, and intestinal tissues. IL1F10 competitively inhibits this interaction, suppressing excessive inflammation and maintaining tissue homeostasis.
Structurally, IL1F10 shares homology with other IL-1 family antagonists, lacking a conserved amino acid motif required for receptor activation. Its recombinant form is typically produced in *E. coli* or mammalian expression systems, ensuring high purity and bioactivity for research or therapeutic applications. Recombinant IL1F10 is instrumental in studying inflammatory diseases, particularly psoriasis, where IL-36 signaling is dysregulated. Clinical studies suggest its potential as a therapeutic agent for psoriasis, acne, and other IL-36-mediated disorders.
Research also highlights IL1F10’s role in modulating adaptive immunity, including T-cell responses, and its involvement in autoimmune conditions like rheumatoid arthritis. Despite promising preclinical data, clinical translation remains in early stages, necessitating further investigation into its pharmacokinetics and long-term safety. Overall, IL1F10 recombinant protein serves as a critical tool for dissecting IL-36 biology and developing targeted anti-inflammatory therapies.
×
